[
  {
    "ts": null,
    "headline": "Abbott Laboratories Second Quarter 2025 Earnings: EPS Beats Expectations",
    "summary": "Abbott Laboratories ( NYSE:ABT ) Second Quarter 2025 Results Key Financial Results Revenue: US$11.1b (up 7.4% from 2Q...",
    "url": "https://finnhub.io/api/news?id=f778362e3aa7105cc307038454ef9ac2dc378707d7809f79fb58866866a1a8c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752932538,
      "headline": "Abbott Laboratories Second Quarter 2025 Earnings: EPS Beats Expectations",
      "id": 136019804,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories ( NYSE:ABT ) Second Quarter 2025 Results Key Financial Results Revenue: US$11.1b (up 7.4% from 2Q...",
      "url": "https://finnhub.io/api/news?id=f778362e3aa7105cc307038454ef9ac2dc378707d7809f79fb58866866a1a8c1"
    }
  },
  {
    "ts": null,
    "headline": "Why AbbVie (ABBV) Remains a Dividend Standout in the Pharma Sector",
    "summary": "AbbVie Inc. (NYSE:ABBV) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. AbbVie Inc. (NYSE:ABBV) stands out as a major player in the pharmaceutical industry, with a broad range of approved treatments. Among its most significant offerings are the immunology drugs Skyrizi and Rinvoq, which are expected to contribute to revenue growth [因",
    "url": "https://finnhub.io/api/news?id=9162f6f1c3067a9dee7149ea4316d163c4b7de7d2bdeacaa97b689bf1aec9b11",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752888909,
      "headline": "Why AbbVie (ABBV) Remains a Dividend Standout in the Pharma Sector",
      "id": 136011821,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. AbbVie Inc. (NYSE:ABBV) stands out as a major player in the pharmaceutical industry, with a broad range of approved treatments. Among its most significant offerings are the immunology drugs Skyrizi and Rinvoq, which are expected to contribute to revenue growth [因",
      "url": "https://finnhub.io/api/news?id=9162f6f1c3067a9dee7149ea4316d163c4b7de7d2bdeacaa97b689bf1aec9b11"
    }
  },
  {
    "ts": null,
    "headline": "How Abbott Laboratories (ABT) Balances Innovation with Shareholder Payouts",
    "summary": "Abbott Laboratories (NYSE:ABT) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. Abbott Laboratories (NYSE:ABT) has long held a strong position in the heavily regulated healthcare industry. Over the years, it has earned the trust of both doctors and consumers, making its well-established brands more appealing in the market. In recent [因",
    "url": "https://finnhub.io/api/news?id=bc4a61f55dc6259fc30322d44bdb536d003e2ac69f8be28175feb970de352819",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752887683,
      "headline": "How Abbott Laboratories (ABT) Balances Innovation with Shareholder Payouts",
      "id": 136011898,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. Abbott Laboratories (NYSE:ABT) has long held a strong position in the heavily regulated healthcare industry. Over the years, it has earned the trust of both doctors and consumers, making its well-established brands more appealing in the market. In recent [因",
      "url": "https://finnhub.io/api/news?id=bc4a61f55dc6259fc30322d44bdb536d003e2ac69f8be28175feb970de352819"
    }
  }
]